Qian Zhang1, Xiaofang Sun2, Xinhua Xiao3, Jia Zheng4, Ming Li5, Miao Yu6, Fan Ping7, Zhixin Wang8, Cuijuan Qi9, Tong Wang10, Xiaojing Wang11. 1. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. zhangqian6088@pumch.cn. 2. Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China. sunxiaofangpu@sohu.com. 3. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. xiaoxh2014@vip.163.com. 4. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. zhengjia_pumch@sohu.com. 5. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. liming_pumch@sohu.com. 6. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. yumiao_pumch@sohu.com. 7. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. fanping_pumch@sohu.com. 8. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. wangzhixinpumch@sohu.com. 9. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. qicuijuan_pumch@sohu.com. 10. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. wangtong_pumch@sohu.com. 11. Key Laboratory of Endocrinology, Ministry of Health, Translational Medical Center, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. wangxiaojingpum@sohu.com.
Abstract
It is now broadly accepted that the nutritional environment in early life is a key factor in susceptibility to metabolic diseases. In this study, we evaluated the effects of maternal chromium restriction in vivo on the modulation of lipid metabolism and the mechanisms involved in this process. Sixteen pregnant C57BL mice were randomly divided into two dietary treatments: a control (C) diet group and a low chromium (L) diet group. The diet treatment was maintained through gestation and lactation period. After weaning, some of the pups continued with either the control diet or low chromium diet (CC or LL), whereas other pups switched to another diet (CL or LC). At 32 weeks of age, serum lipid metabolism, proinflammatory indexes, oxidative stress and anti-oxidant markers, and DNA methylation status in adipose tissue were measured. The results indicated that the maternal low chromium diet increased body weight, fat pad weight, serum triglyceride (TG), low-density lipoprotein cholesterol (LDL), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and oxidized glutathione (GSSG). There was a decrease in serum reduced/oxidized glutathione (GSH/GSSG) ratio at 32 weeks of age in female offspring. From adipose tissue, we identified 1214 individual hypomethylated CpG sites and 411 individual hypermethylated CpG sites in the LC group when compared to the CC group. Pathway analysis of the differential methylation genes revealed a significant increase in hypomethylated genes in the mitogen-activated protein kinase (MAPK) signaling pathway in the LC group. Our study highlights the importance of the MAPK signaling pathway in epigenetic changes involved in the lipid metabolism of the offspring from chromium-restricted dams.
It is now broadly accepted that the nutritional environment in early life is a key factor in susceptibility to metabolic diseases. In this study, we evaluated the effects of maternal chromium restriction in vivo on the modulation of lipid metabolism and the mechanisms involved in this process. Sixteen pregnant C57BL mice were randomly divided into two dietary treatments: a control (C) diet group and a low chromium (L) diet group. The diet treatment was maintained through gestation and lactation period. After weaning, some of the pups continued with either the control diet or low chromium diet (CC or LL), whereas other pups switched to another diet (CL or LC). At 32 weeks of age, serum lipid metabolism, proinflammatory indexes, oxidative stress and anti-oxidant markers, and DNA methylation status in adipose tissue were measured. The results indicated that the maternal low chromium diet increased body weight, fat pad weight, serum triglyceride (TG), low-density lipoprotein cholesterol (LDL), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and oxidized glutathione (GSSG). There was a decrease in serum reduced/oxidized glutathione (GSH/GSSG) ratio at 32 weeks of age in female offspring. From adipose tissue, we identified 1214 individual hypomethylated CpG sites and 411 individual hypermethylated CpG sites in the LC group when compared to the CC group. Pathway analysis of the differential methylation genes revealed a significant increase in hypomethylated genes in the mitogen-activated protein kinase (MAPK) signaling pathway in the LC group. Our study highlights the importance of the MAPK signaling pathway in epigenetic changes involved in the lipid metabolism of the offspring from chromium-restricted dams.
Recently, studies have implied that nutrition during fetal and neonatal life can have profound effects on lifespan, glucose, and lipid metabolism. Human studies conducted in 1944–1945 revealed that undernutrition during early pregnancy was associated with glucose intolerance and increased serum insulin concentrations later in life (50–58 years-old) [1]. It was the first time that scientists addressed the impact of adverse environmental factors in early life on the occurrence of metabolic diseases in adulthood [2]. Later work confirmed and extended this hypothesis by showing significant opposite correlations between birth weight and the risk of adult obesity [3,4]. One important mechanism believed to be involved in this relationship is DNA methylation. DNA methylation changes normally occur within CpG-rich regions (CpG islands). CpG islands are usually located near the promoter regions of genes. Methylation within the promoter region can negatively affect gene expression [5]. DNA methylation is a key regulator of normal metabolic balance and the occurrence of disease [6,7]. DNA methylation changes are particularly sensitive in “early life window period”. DNA methylation changes occurring in utero may be passed on to offspring and may subsequently lead to metabolic diseases [8].An increasing number of studies show that chromium (Cr (III)) supplementation is beneficial in maintaining healthy lipid metabolism, regulating appetite, reducing fat mass, and increasing lean body mass [9]. The minimum suggested daily chromium intake is 30 μg. However, the average dietary chromium intake for adults is far below this recommendation in many countries [10,11]. In particular, pregnant women and elderly individuals are more prone to the chromium deficiency [12], due to increased metabolic stress and decreased absorption ratio [13,14]. Vincent et al. report that a chromium-insufficient diet leads to an increase in serum cholesterol, which can be ameliorated by chromium supplementation [15]. A recent study shows that chronic maternal chromiumdeficiency increases body fat and changes the lipid metabolism in rat pups. The mechanism involved is probably augmented by oxidative stress [16].We hypothesized that exposure to maternal chromium restriction would have a sustained impact on the methylation of genes involved in lipid metabolism, thus lead to dyslipidemia in mice offspring. To identify this epigenetic alteration, we used a genome-wide DNA methylation approach in adipose tissue and tested whether epigenetic changes were associated with differential gene expression.
2. Materials and Methods
2.1. Animals Protocol
This study was performed in strict accordance with the recommendations given by the Guide for the Care and Use of Laboratory Animals from the National Institute of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of Peking Union Medical Hospital (Permit Number: MC-07-6004). All efforts were made to minimize suffering. Seven-week-old C57BL/6J mice (18.5 ± 1.6 g) were acquired from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China, SCXK-2014-0108). After 1 week of adaptation, virgin female C57BL mice were caged with males (2 females to 1 male) overnight. Copulation was confirmed the next morning by establishing the formation of a vaginal plug. Midnight was considered as day 0 of gestation. Pregnant mothers (n = 16) were fed either the control diet (C, n = 8) or low chromium diet (L, n = 8). The control diet was a casein-based diet formulated on the basis of the American Institute of Nutrition AIN-93G diet and contained 1.19 mg/kg chromium. The low chromium diet (reduced only in chromium) contained 0.14 mg/kg chromium (88.23% of chromium restriction compared to control diet). The concentration of dietary chromium was analyzed using an atomic absorption spectrometer (TAS986, Beijing Persee General Corporation, Beijing, China). All diets were produced by Research Diets (New Brunswick, NJ, USA). On day 1 after birth, the litter sizes of both groups were homogenized to six pups (3 male and 3 female mice), to ensure no nutritional bias between litters. The diets were administered throughout gestation and lactation. All offspring was weaned at 3 weeks of age. Following weaning, the offspring were divided into the following sub-groups: CC (control diet-control diet), CL (control diet-low chromium diet), LC (low chromium diet-control diet), and LL (low chromium diet-low chromium diet, n = 8/group, one female pup from each litter was randomly assigned to the experimental groups). The mice were maintained in a light-dark cycle (12 h light and 12 h dark) and were given free access to food and water. Unbalanced maternal nutrition differentially impacted lipid metabolism and phenotypic expression in male and female offspring [17,18]. For this reason, the current study only focused on female offspring. The specific study design is shown in Figure 1. At the end of the experimental period (32 weeks of age), female mice (n = 8/group) were sacrificed. After 10 h of fasting, the mice were anesthetized (ketamine 100 mg/kg i.p., Pharmacia and Upjohn Ltd., Crawley, UK), and blood samples were collected from the intraorbital retrobulbar plexus Adipose tissue of the offspring was quickly collected and stored at −80 °C for further analysis.
Figure 1
The timeline of the animal experiments.
2.2. Serum Chromium Levels
Serum chromium levels in mothers (at weaning) and in the offspring at 32 weeks were determined using an atomic absorption spectrometer (Atomic Absorption Spectrophotometer, Hitachi, Japan).
2.3. Measurement of Body Weight and Food Intake
The body weight of the offspring was recorded at birth, 3 weeks, and 32 weeks of age. Food consumption of the offspring was recorded at 32 weeks. Food consumption was quantified by subtracting the amount of food remaining at the end of the week from the total amount of food given at the beginning of the week. The average amount of food consumed per mouse was determined by dividing the total amount consumed by the number of mice.
2.4. Measurement of Serum Leptin, Adiponectin and Inflammatory Factors
Serum concentrations of leptin, adiponectin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and interleukin-1β (IL-1β) were measured using enzyme-linked immunosorbent assay (ELISA, Abcam, Cambridge, MA, USA).
2.5. Measurement of Serum Oxidative Stress and Antioxidant Markers
Malondialdehyde (MDA) concentration and reduced/oxidized glutathione (GSH/GSSG) were measured using thiobarbituric acid (TBA) and Thiol Green Indicator fluorometric method (Abcam, Cambridge, MA, USA) as oxidative stress and antioxidant markers, respectively.
2.6. Measurement of Serum Total Cholesterol (TC), Triglyceride (TG), High-Density Lipoproterin Cholesterol (HDL), and Low-Density Lipoprotein Cholesterol (LDL)
Serum TC, TG, HDL, and LDL concentrations were determined using an enzyme end-point method via a commercial kit (Roche Diagnostics, GmbH, Mannheim, Germany).
2.7. Measurement of Adipose Tissue Weight
At 32 weeks, mice were sacrificed and retroperitoneal, mesenteric, and ovarian fat were carefully removed and weighed. The adiposity index (AI) was computed as followings [19],
2.8. Methyl-DNA Immunoprecipitation and Microarray Hybridization
Fat collected from three CC mice and LCmice was used for methyl-DNA immunoprecipitation (MeDIP) experiment. Genomic DNA (gDNA) was extracted from fat samples using a DNeasy Blood & Tissue Kit (Qiangen, Fremont, CA, USA). The purified gDNA was then quantified and quality was assessed using Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). To perform the MeDIP experiment, first, gDNA was sonicated into random 200–1000 bp pieces. Next, 1 µg of fragmented DNA was used for immunoprecipitation with mouse monoclonal anti-5-methylcytidine (Diagenode, Liege, Belgium) at 4 °C overnight. To recover the immunoprecipitated DNA fragments, anti-mouse IgG magnetic beads (ThermoFisher Scientific, Carlsbad, CA, USA) were added and incubated for an additional 2 h at 4 °C with agitation. Then, immunoprecipitated methylated DNA and input gDNA was labeled with Cy5 and Cy3 fluorophores, respectively. Labelled DNA was hybridized to the Arraystar Mouse ReqSeq Promoter Array (Agilent, Waldbronn, Germany). This array contained all well-characterized RefSeq gene (approximately 22,327 genes) promoter regions (from −1300 bp to 500 bp transcription start sites (TSSs)). Finally, arrays were washed and scanned with an Agilent Scanner G2505C (Agilent Technologies, Waldbronn, Germany). After normalization, methylation peaks in the raw data were analyzed using SignalMap software (Roche Diagnostics, GmbH, Mannheim, Germany). We computed the modified Kolmogorov–Smirnov test on the adjacent probes using sliding windows to predict enriched regions across the array. To separate strong CpG islands from weak CpG islands, promoters were categorized into three levels: high CpG promoters/regions (HCP), intermediate CpG promoters/regions (ICP) and low CpG promoters/regions (LCP) [20].
To determine the biological meaning to the differentially methylated genes, the subset of methylated genes was analyzed by applying the Gene Ontology (GO) classification system and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways database using DAVID (Database for Annotation, Visualization and Integrated Discovery) software [21].
2.10. Bisulfite Sequencing (BSP)
Bisulfite modification was performed with the EZ DNA Methylation Kit (Zymo Research, Hiss Diagnostics, Germany). The converted DNA was then amplified by PCR with primers detailed in Table 1. Primers were designed using Methyl Primer Express Software version 1.0 (Applied Biosystems, Foster City, CA, USA). PCR products were purified using agarose gels (Invitrogen, Carlsbad, CA, USA) and ligated to the pMD18-T Vector (Takara, Shiga, Japan). The plasmids were then purified using the PureLink Miniprep kit (Invitrogen, Thermo Scientific Inc., Waltham, MA, USA). Positive clones were confirmed by PCR, and a minimum of 10 clones from each mouse (n = 8 mice/group) were sequenced using ABI PRISM 7700 Sequence Detection (Applied Biosystems, Foster City, CA, USA). Sequence analysis was performed using QUMA [22].
Table 1
PCR Primers for bisulfite sequencing.
Gene
Accession Number
Primer Sequences (from 5′ to 3′)
Production Size
CpG Number
Map3k4
NM_011948
F: 5′-AATGATTGAAAGATGTTTTGTT-3′
303
5
R: 5′-TTCATAAACTAAAACTCAAAATCTC-3′
Mapk14
NM_001168513
F: 5′-GGAGTAAGTAGGGTGGTTTTGT-3′
382
30
R: 5′-CAAACTTTACCCTACAACTCCTC-3′
Map3k5
NM_008580
F: 5′-GTAAGGGAGTTGTTGYGGAGTA-3′
258
35
R: 5′-AAAAAAACAAAACTTCCTCCTCTT-3′
Tab2
NM_138667
F: 5′-TGTTGATTAAGGAAAGTTTAGYG-3′
252
34
R: 5′-CRAAACCCTACAAACCCTAAC-3′
PCR: Polymerase Chain Reaction; Map3k4: mitogen-activated protein kinase kinase kinase 4; Mapk14: mitogen-activated protein kinase 14; Map3k5: mitogen-activated protein kinase kinase kinase 5; Tab2: transforming growth factor-β (TGF-β)-activated kinase 1/MAP3K7 binding protein 2.
2.11. Quantitative Real Time RT-PCR
The data (n = 8/group) were further analyzed for the expression of BSP-validated genes and downstream genes. The total RNA was prepared from fat stored at −80 °C using the Qiagen RNeasy Mini Kit (Qiagen, Germantown, MD, USA). cDNA was synthesized from the reverse transcription of the total RNA using an oligodesoxythymidine primer and the TakaRa RT kit (Takara, Shiga, Japan). The experimental real-time PCR signals were normalized to that of Gadph gene. Real-time amplification was performed using the ABI 7900 thermocycler (Applied Biosystems, Foster City, CA, USA). The fold change was calculated using the comparative Ct method. The primer sequences for quantitative real-time PCR are shown in Table 2.
Table 2
Primer using in real time PCR.
Gene
Accession Number
Primer Sequences (from 5′ to 3′)
Production Size
Map3k4
NM_011948
F: 5′-ATTGGAGAAGGACAGTAT-3′
107
R: 5′-ATAGTCTTGTGGTCGTTA-3′
Mapk14
NM_001168513
F: 5′-TGTTCTGTCTATCTCACTTC-3′
75
R: 5′-GAGGCACTTGAATGGTAT-3′
Map3k5
NM_008580
F: 5′-AATAATGAAGTTGAGGAGAAGACA-3′
78
R: 5′-AGAGGAAGCACCGAAGTT-3′
Tab2
NM_138667
F: 5′-TATCAGTGCTTGGAATGG-3′
143
R: 5′-GACCTTCTTAACGCTCAT-3′
Pparg
NM_001127330
F: 5′-GCATCAGGCTTCCACTAT-3′
75
R: 5′-CTTCAATCGGATGGTTCTTC-3′
Atf2
NM_001025093
F: 5′-GGCGTTCAAGCAGGATTC-3′
106
R: 5′-TGACACTGAGACCATAGCAATA-3′
Map3k4: mitogen-activated protein kinase kinase kinase 4; Mapk14: mitogen-activated protein kinase 14; Map3k5: mitogen-activated protein kinase kinase kinase 5; Tab2: TGF-β-activated kinase 1/MAP3K7 binding protein 2; Pparg: peroxisome proliferator activated receptor gammas; Atf2: activating transcription factor 2.
2.12. Statistical Analysis
Results are shown as means ± SD; n represents the number of mice analyzed. Unpaired Student’s t test was used to compare the two groups, and one-way ANOVA followed by Tukey’s post hoc test was used when more than two groups were analyzed. For GO and KEGG pathway analysis, Fisher’s exact test was used. A p value < 0.05 was considered significant. Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis.
3. Results
3.1. Maternal Body Weight and Serum Chromium Differences
By the end of lactation, there was no significant difference in maternal body weight between the C dams and L dams (Table 3). As expected, the serum chromium levels were significantly decreased in the L group when compared to the C group (p < 0.01, Table 3).
Table 3
Body weight, fasting blood glucose and serum chromium level in dams at weaning.
Groups
C
L
Body weight (g)
23.1 ± 3.5
22.3 ± 3.4
Serum chromium (ng/mL)
0.89 ± 0.22
0.45 ± 0.09 **
C, control diet group; L, low chromium diet group. Values are mean ± SD, n = 8 per group. ** p < 0.01 vs. C.
3.2. Effects in Offspring
3.2.1. Effects of Maternal Low Chromium Diet on Serum Chromium Level, Body Weight, Food Intake, and Fat Pad Weight in Offspring
At week 32, serum chromium levels were lower in the LL and CL groups when compared to the CC group (p < 0.01, Figure 2a). Serum chromium levels in the LC group returned to normal (Figure 2a). The birth weight of L group and C group offspring were comparable (Figure 2b). At weaning, there was still no significant difference in body weight between L and C group (Figure 2c). Although food intake was comparable between the groups (Figure 2e), body weight in the LL group and the CL group were higher than those in CC group at 32 weeks of age (p < 0.05, Figure 2d). The body weights of the LC group were higher than those of CC group (p < 0.05, Figure 3d). At 32 weeks of age, body fat pad weights were significantly higher in the LL and CL group offspring when compared to those of the offspring from the CC group (p < 0.01, Figure 2f). Rehabilitation of low chromium diet dams (LC group) did not correct fat pad weight (p < 0.01, Figure 2f).
Figure 2
Effects of maternal low chromium diet on serum chromium (a); body weight (d); food intake (e); fat pad weight (f); serum total cholesterol (g); triglyceride (h); HDL (i) and LDL (j); leptin (k); adiponectin (l); TNF-α(m); IL-6 (n); IL-1β (o); MDA (p); GSH (q); GSSG (r); GSH/GSSG (s) at 32 weeks of age; birth weight (b) and weaning weight (c). Values are mean ± SD, n = 8 per group. * p < 0.05, ** p < 0.01.
Figure 3
Distribution of differentially methylated promoters on chromosomes (a) and promoters with respect to the cytosine polyguanine (CpG) content (b), including high CpG promoters/regions (HCP), intermediate CpG promoters/regions (ICP), and low CpG promoters/regions (LCP)in low chromium diet-control diet (LC) group.
3.2.2. Effects of Maternal Low Chromium Diet on Serum Lipid Profile in Offspring
Serum TG levels were significantly higher in the LL and LC groups’ offspring when compared to those of the CC group (Figure 2h, p < 0.05). LDL in the LL group was higher than the CC group (p < 0.05, Figure 2j). However, LDL levels were corrected in the LC group. At 32 weeks of age, serum TC and HDL were not significantly different among the offspring across all groups (Figure 2g,i).
3.2.3. Effects of Maternal Low Chromium Diet on Serum Adiponectin, Leptin, and Pre-Inflammation Cytokines in Offspring
There was no significant differences among the groups in serum adiponectin, leptin, IL-6, and IL-1β values at 32 weeks of age (Figure 2k,l,n,o). Only serum TNF-α levels were significantly higher in the LL, LC, and CL groups when compared to that of the CC group (Figure 2m, p < 0.05).
3.2.4. Effects of Maternal Low Chromium Diet on Serum Oxidative Stress and Antioxidant Markers in Offspring
Serum MDA levels were significantly higher in the LC and LL group when compared to that of the CC group at 32 weeks of age (Figure 2p, p < 0.01 and p < 0.05, respectively). There was no significant difference among the groups in serum GSH (Figure 2q). Serum GSSG levels were significantly higher in LC, CL, and LL groups than that in CC group (Figure 2r, p < 0.01). Thus, serum GSH/GSSG ratio was significant lower in LC, CL, and LL groups than CC group (Figure 2s, p < 0.01).
3.2.5. Effects of Maternal Low Chromium Diet on Genome-Wide DNA Methylation in Adipose Tissue Collected from Offspring
First, we obtained a CpG promoter methylation profile of the LC group and compared it to that of the CC group (GEO database: GSE82030). This comparison showed that 4.8% (1214 loci) of promoters in 1145 genes were hypomethylated in the LC group, particularly on chromosomes 2, 4, 5, 7, 9, 11, and 17, which have more promoters with differential methylation (Peak Score > 2). In contrast, fewer promoters showed a trend toward hypermethylation in the LC group, just 1.8% (411 loci) of promoters (Figure 3a). Among the hypomethylated promoters, 963 (79.3%) were located in HCP, 188 (15.5%) in ICP, and 63 (5.2%) in LCP. And among hypermethylated promoters, 73 (17.8%) were located in HCP, 90 (21.9%) in ICP, and 248 (60.3%) in LCP (Figure 3b).
3.2.6. Functional Analysis Using DAVID
Next, functional analysis of hypomethylated genes was performed. Function analysis revealed that hypomethylated genes were involved in the regulation of transcript, transcription, chromatin organization, and so on (Table 4, Figure 4). Biological pathway impacted by hypomethylated genes include gap junction and the mitogen-activated protein kinase (MAPK) signaling pathway (Table 5). Figure 5 and Table 6 illustrate that the MAPK signaling pathway in the LC group affected genes exhibiting promoter hypomethylation in the LC group; this was in contrast to what was observed in the CC group.
Table 4
Annotation of LC group hypomethylated promoter genes (p value < 0.00001).
Term
Term Number
Count
p-Value
Fold Enrichment
Biological process
-
-
-
-
regulation of transcription
GO:0045449
189
1.83×10−9
1.5015
transcription
GO:0006350
158
2.21×10−9
1.5775
chromatin organization
GO:0006325
43
1.75×10−7
2.4151
chromatin modification
GO:0016568
33
3.57×10−6
2.4737
chromosome organization
GO:0051276
46
9.60×10−6
2.0145
regulation of transcription from RNA polymerase II promoter
GO:0006357
62
1.19×10−5
1.7807
regulation of transcription, DNA-dependent
GO:0006355
118
5.50×10−5
1.4250
negative regulation of transcription, DNA-dependent
GO:0045892
36
6.18×10−5
2.0679
negative regulation of gene expression
GO:0010629
44
6.38×10−5
1.8987
negative regulation of transcription
GO:0016481
41
6.63×10−5
1.9500
regulation of RNA metabolic process
GO:0051252
119
6.89×10−5
1.4149
negative regulation of RNA metabolic process
GO:0051253
36
7.05×10−5
2.0546
glycoprotein biosynthetic process
GO:0009101
19
9.41×10−5
2.8731
Cellular componts
-
-
-
-
nuclear lumen
GO:0031981
86
2.10×10−8
1.8592
intracellular organelle lumen
GO:0070013
101
8.79×10−8
1.7017
organelle lumen
GO:0043233
101
1.00×10−7
1.6972
endomembrane system
GO:0012505
58
2.07×10−7
2.0695
membrane-enclosed lumen
GO:0031974
102
2.64×10−7
1.6585
Golgi apparatus
GO:0005794
68
3.70×10−7
1.9034
nucleoplasm
GO:0005654
57
1.54×10−5
1.8165
Golgi apparatus part
GO:0044431
29
2.07×10−5
2.4388
Golgi membrane
GO:0000139
20
9.16×10−5
2.7868
Molecular Function
-
-
-
-
DNA binding
GO:0003677
167
1.62×10−12
1.6952
transcription regulator activity
GO:0030528
113
1.85×10−8
1.6939
transcription factor activity
GO:0003700
76
1.22×10−6
1.7706
metal ion binding
GO:0046872
260
8.05×10−5
1.2209
cation binding
GO:0043169
262
8.06×10−5
1.2192
Figure 4
Gene ontology classifications in biology process for hypomethylated genes. The gene ontology (GO) term is on the y-axis, number of genes is on the x-axis, and the p-value indicating significance of enrichment is on the right side.
Table 5
KEGG pathway in LC group hypomethylated genes (p < 0.01).
Pathway Name
Pathway Term
Gene Count
Fold Enrichment
p-Value
Gap junction
mmu04540
11
2.6025
0.008845
MAPK signaling pathway
mmu04010
23
1.7660
0.009097
Figure 5
Promoter-specific DNA methylation of genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) mitogen-activated protein kinase (MAPK) signaling pathway. The red box indicates hypomethylated gene promoters and the map was provided by KEGG Pathway Database.
Table 6
LC group hypomethylation genes in MAPK signaling pathway (peak score > 2).
Gene Name
Accession
Chromosome
Peak to TSS
Promoter Classification
Peak Score
Peak M Value
Rac1
NM_009007
chr5
264
HCP
2.42
0.550
Rela
NM_009045
chr19
349
HCP
2.65
0.477
Prkcb
NM_008855
chr7
350
HCP
2.96
0.370
Cacna1h
NM_001163691
chr17
37
HCP
3.1
0.338
Map3k4
NM_011948
chr17
−422
HCP
3.48
0.334
Tab2
NM_138667
chr10
−175
HCP
3.68
0.312
Fgf3
NM_008007
chr7
336
HCP
2.08
0.305
Braf
NM_139294
chr6
105
HCP
2.48
0.265
Mapk14
NM_001168513
chr17
−833
HCP
3.38
0.259
Mapk14
NM_001168514
chr17
393
HCP
3.38
0.259
Fgf18
NM_008005
chr11
85
HCP
2.93
0.258
Map3k5
NM_008580
chr10
−291
HCP
2.6
0.254
Cacna2d3
NM_009785
chr14
−314
HCP
2.94
0.251
Pdgfa
NM_008808
chr5
−301
HCP
3.42
0.247
Fgf8
NM_010205
chr19
−231
HCP
2.59
0.218
Cacnb4
NM_001037099
chr2
145
ICP
2.27
0.169
Fgf11
NM_010198
chr11
117
ICP
2.11
0.144
Hras1
NM_001130444
chr7
−254
HCP
2.36
0.121
Sos1
NM_009231
chr17
−350
HCP
2.49
0.109
Cacna1g
NM_001177890
chr11
−401
HCP
2.15
0.060
1500003O03Rik
NM_019769
chr2
437
HCP
2.37
0.053
Dusp16
NM_130447
chr6
−410
HCP
2.18
0.038
Prkx
NM_016979
chrX
−253
HCP
2.22
0.035
Nfkb2
NM_001177370
chr19
−536
ICP
2.1
0.012
TSS, transcription start sites; Peak to TSS, the distance from the center of the peak to the TSS. (“-”: peak center in upstream of the TSS); Peak Score, the average of −log10−value from the probes within the peak. The score reflects the probability of positive enrichment. (cut-off = 2); Peak M Value, the median of log2−ratio from the probes within the peak. The score reflects the methylation degree; HCP, high CpG promoters/regions; ICP, intermediate CpG promoters/regions; LCP, low CpG promoters/regions.
3.2.7. Bisulfite Sequencing (BSP)
Bisulfite Sequencing (BSP) on four hypomethylated promoters was performed. Five to 35 CpGs for each gene were involved in the analysis. The methylation percentages of these promoters are shown in Figure 6a–e. Mitogen-activated protein kinase kinase kinase 4 (Map3k4), mitogen-activated protein kinase kinase kinase 5 (Map3k5), mitogen-activated protein kinase 14 (Mapk14), and TGF-β-activated kinase 1/MAP3K7 binding protein 2 (Tab2) were significantly hypomethylated in the LC group, compared to the CC group (p < 0.05). This result confirmed the results acquired using the DNA methylation array.
Figure 6
Effects of maternal low chromium diet on methylation of Map3k4 (a); Mapk14 (b); Map3k5 (c); and Tab2 (d) and relative expression (f) of genes in adipose of offspring. For bisulfite sequencing (BSP) results, white circles represent unmethylated CpGs, and black circles represent methylated CpGs (a–d); figure e shows the analysis of DNA methylation status. Values are expressed as means ± SD, n = 8 per group. For BSP, pooled DNA of eight mice adipose for each group is what we used for analysis. For each gene in each group, 10 clones randomly selected were analyzed and represent the average methylation level for the indicated genes. * p < 0.05, **p < 0.01, vs. CC. Map3k4: mitogen-activated protein kinase kinase kinase 4; Mapk14: mitogen-activated protein kinase 14; Map3k5: mitogen-activated protein kinase kinase kinase 5; Tab2: TGF-β-activated kinase 1/MAP3K7 binding protein 2; Pparg: peroxisome proliferator activated receptor gammas; Atf2: activating transcription factor 2.
3.2.8. Real-Time RT PCR Assay for BSP-Validated Hypomethylated Genes and Downstream Genes
To explore whether hypomethylated promoters can affect gene expression, the expression of four genes (Map3k4, Map3k5, Mapk14, and Tab2) regulated by these hypomethylated promoters and two downstream genes (Atf2, Pparg) was analyzed by real-time PCR. The results showed that the LC group had significantly high expression levels of Map3k4, Map3k5, Mapk14, Tab2, Atf2, and Pparg compared to CC group (p < 0.01, Figure 6f).
4. Discussion
Most importantly, in this study we found that body weight was comparable among the different groups at birth and at 3 weeks of age. However, at 32 weeks, pups from low chromium diet dams were heavier than those of the control group. Switching to the control diet did not correct the body weight increase. Other studies have reported that maternal chromium restriction significantly increased body weight from 12 months of age. Rehabilitation regimes did not correct the change [16]. It has also been reported that dietary vitamin B12 restriction increased body weight from weaning [23].In our study, food intake was comparable among all groups at 32 weeks. However, maternal chromium restriction increased fat pad weight in offspring at 32 weeks of age. Reversing the diet did not correct this change. Venu et al. found that offspring from vitamin-restricted dams had a significantly higher percentage of body adipose from day 100 [24].In addition, maternal chromium restriction may increase serum TG and LDL in offspring at 32 weeks of age; reversing the diet corrected LDL levels only. Other groups have found that maternal vitamin or chromium restriction may also significantly increase circulating triglyceride levels [16,24].Moreover, maternal chromium restriction may increase serum TNF-α levels. TNF-α modulates lipid metabolism and is associated with obesity. The long-term effect of maternal magnesium restriction increases plasma TNF-α in offspring at 18 months [25]. Several groups found that maternal protein restriction upregulated TNF-α expression in the liver and spleen, and increased serum TNF-α from fetal age to adulthood [26,27,28].Early nutritional exposures can affect later disease risk through the epigenomic changes (DNA methylation, histone modifications, and so on). Although these epigenomic changes do not directly affect the DNA nucleotide sequence, it can be passed on to subsequent generations [8]. DNA methylation, which usually occurs at cytosines within CpG islands, is a key regulator in gene transcription. CpG islands are usually located in or near the promoters of the genes [29,30]. The DNA methylation changes in promoter regions are negatively related to gene expression [31].After genome-wide screening for differentially methylated promoters, we found that MAPK signaling was located at the center of many different methylated genes (Figure 7), such as Map3k4, Mapk14, Map3k5, Tab2. MAPKs can regulate many cellular processes, such as normal cell proliferation, differentiation, and apoptosis [32]. More and more evidence shows that MAPK-dependent signal transduction is related to adipogenesis [33,34]. The MAPK family consists of three main members: extracellular signal-regulated protein kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinases. Inflammatory cytokines and many other cellular stresses may activate the p38 MAPK pathway. The p38 MAPK takes part in apoptosis and cell cycle regulation [35]. Transforming growth factor-β-activated kinase 1 (TAK1) belongs to the MAPK family [36]. TAK1 activity is regulated by TAB1, TAB2, TAB3, and TAB4 [37,38]. The activated TAK1 induces the activation of p38 MAPK. Liu et al. found TNF-α markedly promotes the interaction between TAB2 and TAK1, leading to the phosphorylation of p38 MAPK. Pre-treatment with docosahexaenoic acid (DHA) can block the interaction between TAB2 and TAK1 and can attenuate the TNF-α-induced phosphorylation of ERK [39]. We found that maternal low chromium diet could lead to the demethylation of TAB2 and p38, and activation of Tab2 and p38 expression. Finer et al. found that maternal gestational diabetes leads to genome-wide DNA methylation difference in the placenta and cord blood of exposed offspring. Pathways involved in MAPK signaling are enhanced in methylation genes [40]. Nyggf4, which is a newly discovered obesity candidate gene, may regulate the methylation levels of various isoforms of the MAPK subfamily [41].
Figure 7
The possible mechanism of maternal chromium restriction on offspring. Maternal chromium restriction induces oxidative stress, then leads to hypomethylate in Map3k5 (Ask1), Tab2, Map3k4 (Mekk4), Mapk14 (p38 MAPK) promoter, activates Ppar-γ through Atf-2 to accelerate adipogenesis in adipose of mice offspring. The red box indicates hypomethylated gene promoters, and upregulated gene expression. Map3k4: mitogen-activated protein kinase kinase kinase 4; Mapk14: mitogen-activated protein kinase 14; Map3k5: mitogen-activated protein kinase kinase kinase 5; Tab2: TGF-beta activated kinase 1/MAP3K7 binding protein 2; Tak1: Transforming growth factor-β-activated kinase 1; Ask1: apoptosis signal-regulated kinase 1; Mkk3/6: mitogen-activated protein kinase kinase 3/6; Pparγ: peroxisome proliferator activated receptor gammas; Atf2: activating transcription factor 2.
MAPK family is sensible to imbalance of antioxidant system [42]. Our research found that maternal chromium restriction increased serum MDA level and reduced GSH/GSSG ratio in offspring. Indeed, the measurement of oxidative stress and antioxidant markers is often disturbed by interference from the assay or overestimation derived form stressing analysis conditions. However, MDA is an end-product of lipid hydroperoxide and a widely used marker of the status of oxidative stress [43]. And GSH is a critical antioxidants in vivo. It can neutralize reactive oxygen species through converting to GSSG. Reduction of the GSH/GSSH ratio is an important biomarker of oxidative stress [44]. Saben et al. identified pathways affected by oxidative stress significantly increased in placenta from obesewomen [45]. Maternal low protein diet increases oxidative stress and reduces anti-oxidant enzyme activity in placenta and fetal livers of rats [46]. Oxidative stress is one mechanism programming offspring metabolic outcomes.P38 MAPK can activate PPARγ through activating transcription factor-2 (ATF-2) [47,48]. PPARγ is a key transcription factor medicating adipocyte differentiation [49]. Our result also showed that maternal chromium restriction activate the expression of Atp2 and Pparg in adipose of mice offspring. Activated Pparg induces the expression of lipolytic (lipoprotein lipase) and lipogenic (fatty acid synthase) enzymes, which modulate fatty acid uptake and synthesis [50,51]. Increased PPARγ levels are observed in the adipose tissue of obese animals and humans [52,53,54]. Ahmad et al. found a significant upregulation of hepatic PPARγ expression in 12 months old rat pups born to vitamin B12-deficient mothers [55].
5. Conclusions
In summary, this study is the first to demonstrate a linkage among maternal low chromium diet, the regulation of methylation levels in MAPK pathway genes, and dysfunctional lipid metabolism in offspring. This could lead to adipogenesis and lipogenesis and could contribute to an enhanced susceptibility to the development of obesity in later life. Identifying the biological underpinnings of these mechanisms could help us find early interventional treatments for offspring due to maternal undernutrition. Based on the results revealed by this study, the MAPK pathway genes methylation could be considered as a possible target to modulate the development of lipid dysfunction in the offspring born from mothers with chromium restriction diet during pregnancy.
Authors: K Yamaguchi; K Shirakabe; H Shibuya; K Irie; I Oishi; N Ueno; T Taniguchi; E Nishida; K Matsumoto Journal: Science Date: 1995-12-22 Impact factor: 47.728
Authors: Isabele Bringhenti; Alini Schultz; Tamiris Rachid; Marco A Bomfim; Carlos A Mandarim-de-Lacerda; Marcia B Aguila Journal: J Nutr Biochem Date: 2010-12-28 Impact factor: 6.048
Authors: J Saben; F Lindsey; Y Zhong; K Thakali; T M Badger; A Andres; H Gomez-Acevedo; K Shankar Journal: Placenta Date: 2014-01-11 Impact factor: 3.481
Authors: Tiffany C Armenta; Steve W Cole; Daniel H Geschwind; Daniel T Blumstein; Robert K Wayne Journal: Behav Ecol Date: 2018-12-17 Impact factor: 2.671